Citation Impact
Citing Papers
2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy
2014 Standout
2014 AHA/ACC Guideline for the Management of Patients With Valvular Heart Disease
2014 Standout
2014 AHA/ACC Guideline for the Management of Patients With Valvular Heart Disease
2014 Standout
2014 AHA/ACC Guideline for the Management of Patients With Valvular Heart Disease: Executive Summary
2014 Standout
Orantinib versus placebo combined with transcatheter arterial chemoembolisation in patients with unresectable hepatocellular carcinoma (ORIENTAL): a randomised, double-blind, placebo-controlled, multicentre, phase 3 study
2017
Evaluation and Management of the Child and Adult With Fontan Circulation: A Scientific Statement From the American Heart Association
2019
Hepatocellular carcinoma
2018 Standout
Updated use of TACE for hepatocellular carcinoma treatment: How and when to use it based on clinical evidence
2018
Locoregional therapies in the era of molecular and immune treatments for hepatocellular carcinoma
2021
Hepatocellular carcinoma
2021 Standout
A global view of hepatocellular carcinoma: trends, risk, prevention and management
2019 Standout
BCLC strategy for prognosis prediction and treatment recommendation: The 2022 update
2021 Standout
Choosing the best contraceptive method for the adult with congenital heart disease
2009
Pyroptosis: mechanisms and diseases
2021 Standout
Hepatocellular carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
2018
Guidelines for the diagnosis and management of intrahepatic cholangiocarcinoma
2014 Standout
The treatment of intermediate stage tumours beyond TACE: From surgery to systemic therapy
2017
The immunology of hepatocellular carcinoma
2018
Mechanisms of Bone Metastasis
2004 Standout
Molecular therapies and precision medicine for hepatocellular carcinoma
2018
Long-term Issues After the Fontan Procedure
2013
22q11.2 deletion syndrome
2015 Standout
Diagnosis, Treatment, and Long-Term Management of Kawasaki Disease: A Scientific Statement for Health Professionals From the American Heart Association
2017 Standout
Hepatocellular carcinoma
2022 Standout
2021 Guideline for the Prevention of Stroke in Patients With Stroke and Transient Ischemic Attack: A Guideline From the American Heart Association/American Stroke Association
2021 Standout
Local and Regional Therapies for Hepatocellular Carcinoma
2020
2018 AHA/ACC Guideline for the Management of Adults With Congenital Heart Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines
2018
Hepatocellular Carcinoma
2019 Standout
Hemodynamic Phenotype of the Failing Fontan in an Adult Population
2013
ACC/AHA 2008 Guidelines for the Management of Adults With Congenital Heart Disease: Executive Summary
2008 Standout
Use of zoledronate to treat osteoblastic versus osteolytic lesions in a severe-combined-immunodeficient mouse model.
2002
Trial Design and Endpoints in Hepatocellular Carcinoma: AASLD Consensus Conference
2020
Diagnosis, Staging, and Management of Hepatocellular Carcinoma: 2018 Practice Guidance by the American Association for the Study of Liver Diseases
2018 Standout
2020 ACC/AHA Guideline for the Management of Patients With Valvular Heart Disease: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines
2020 Standout
EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma
2018 Standout
2015 ESC Guidelines for the management of infective endocarditis
2015 Standout
2008 Focused Update Incorporated Into the ACC/AHA 2006 Guidelines for the Management of Patients With Valvular Heart Disease
2008 Standout
Neurodevelopmental Outcomes in Children With Congenital Heart Disease: Evaluation and Management
2012 Standout
Works of Nigel Hacking being referenced
Distribution of Bony Metastases in Prostatic Carcinoma
1990
Direct Measurement of Porto-systemic Gradient in a Failing Fontan Circulation
2011
Sorafenib in combination with transarterial chemoembolisation in patients with unresectable hepatocellular carcinoma (TACE 2): a randomised placebo-controlled, double-blind, phase 3 trial
2017
Arterialised hepatic nodules in the Fontan circulation: Hepatico-cardiac interactions
2010
Hepatic changes in the failing Fontan circulation
2006
TACE 2: A randomized placebo-controlled, double-blinded, phase III trial evaluating sorafenib in combination with transarterial chemoembolisation (TACE) in patients with unresectable hepatocellular carcinoma (HCC)—Background.
2016
TACE 2: A randomized placebo-controlled, double-blinded, phase III trial evaluating sorafenib in combination with transarterial chemoembolisation (TACE) in patients with unresectable hepatocellular carcinoma (HCC).
2012